

# Establishment of A Protocol for *In Vitro* Culture of Cardiogenic Mesodermal Cells Derived from Human Embryonic Stem Cells

Sadaf Vahdat, M.Sc.<sup>1,2</sup>, Sara Pahlavan, Ph.D.<sup>2</sup>, Nasser Aghdami, Ph.D.<sup>2</sup>, Behnaz Bakhshandeh, Ph.D.<sup>1\*</sup>, Hossein Baharvand, Ph.D.<sup>2,3\*</sup>

1. Department of Biotechnology, College of Science, University of Tehran, Tehran, Iran

2. Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran

3. Department of Developmental Biology, University of Science and Culture, Tehran, Iran

\*Corresponding Addresses: P.O. Box: 14155-6455, Department of Biotechnology, College of Science, University of Tehran, Tehran, Iran  
P.O.Box: 16635-148, Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran  
Emails: b.bakhshandeh@ut.ac.ir, baharvand@royaninstitute.org

Received: 9/Dec/2017, Accepted: 19/Feb/2018

## Abstract

**Objective:** Cardiovascular progenitor cells (CPCs) are introduced as one of the promising cell sources for preclinical studies and regenerative medicine. One of the earliest type of CPCs is cardiogenic mesoderm cells (CMCs), which have the capability to generate all types of cardiac lineage derivatives. In order to benefit from CMCs, development of an efficient culture strategy is required. We aim to explore an optimized culture condition that uses human embryonic stem cell (hESC)-derived CMCs.

**Materials and Methods:** In this experimental study, hESCs were expanded and induced toward cardiac lineage in a suspension culture. Mesoderm posterior 1-positive (MESP1<sup>+</sup>) CMCs were subjected to four different culture conditions: i. Suspension culture of CMC spheroids, ii. Adherent culture of CMC spheroids, iii. Adherent culture of single CMCs using gelatin, and iv. Adherent culture of single CMCs using Matrigel.

**Results:** Although, we observed no substantial changes in the percentage of MESP1<sup>+</sup> cells in different culture conditions, there were significantly higher viability and total cell numbers in CMCs cultured on Matrigel (condition iv) compared to the other groups. CMCs cultivated on Matrigel maintained their progenitor cell signature, which included the tendency for cardiogenic differentiation.

**Conclusion:** These results showed the efficacy of an adherent culture on Matrigel for hESC-derived CMCs, which would facilitate their use for future applications.

**Keywords:** Cardiomyocytes, Cell Differentiation, Matrigel, Multipotent Stem Cells

Cell Journal (Yakhteh), Vol 20, No 4, Jan-Mar (Winter) 2019, Pages: 496-504

**Citation:** Vahdat S, Pahlavan S, Aghdami N, Bakhshandeh B, Baharvand H. Establishment of a protocol for in vitro culture of cardiogenic mesodermal cells derived from human embryonic stem cells. Cell J. 2019; 20(4): 496-504. doi: 10.22074/cellj.2019.5661.

## Introduction

Cardiovascular progenitor cells (CPCs) are proliferative multipotent cardiac-committed cells that can generate all main types of cardiac cells (cardiomyocytes, endothelial and smooth muscle cells) *in vitro* and *in vivo* (1). They are widely used in various experimental and clinical studies. CPCs are considered superior candidates for cardiac cell therapy due to their cardiac regeneration capacity where they have the capability to replace dead myocardium as well as exert paracrine effects (2-4). These progenitor cells can be isolated from the biopsy of a patient's heart, expanded *in vitro*, and transplanted back to the heart as autologous cells (5).

However, increased age affects the functionality and proliferative capacity of patient-derived CPCs (5). Today, CPCs can be differentiated from all sources of human pluripotent stem cells (hPSCs) such as human embryonic stem cells (hESCs) and

human induced pluripotent stem cells (hiPSCs). CPCs are considered an alternative and readily available source for experimental and clinical applications (6-9). There are a number of well-established protocols that differentiate hPSCs toward cardiac lineages by manipulating signaling pathways involved in cardiogenesis. Therefore, hPSCs can be used for generation and specification of CPCs (10-12).

hPSC-derived CPCs can successfully differentiate into all 3 types of cardiac lineages *in vitro* and could improve cardiac function after transplantation into animal models of myocardial infarction (13-15). All CPC types arise from a common ancestor progenitor cell, which is featured by the expression of mesoderm posterior 1 (*MESPI*) transcription factor. *MESPI* expression is specific to the early stage of heart development and considered to be the master regulator of cardiac development. Therefore, it is an appropriate marker for isolation of early CPCs,

or cardiogenic mesoderm cells (CMCs) (16-18). Despite the importance of MESP1<sup>+</sup> CMCs in normal heart development and their potential application *in vitro* as well as clinical preparations (19-21), no optimum condition exists for their culture. Therefore, development of an efficient culture condition that can retain cellular features and provide the possibility of further manipulations are inevitably required.

In this study, we aimed to establish an efficient culture condition for hESC-derived CMCs. CMCs were more than 80% positive for MESP1 and expressed cardiac transcription factors. Their differentiation potency toward cardiomyocytes were preserved as shown by induction of both spontaneous and directed differentiation.

## Materials and Methods

### Expansion of human embryonic stem cells in suspension culture

In this experimental study, hESCs (RH5 line) were cultured and expanded as spheroids according to a previously described protocol (22). Briefly,  $2 \times 10^5$  viable cells/ml were cultured in hESC medium that consisted of Dulbecco's Modified Eagle Medium/Ham's F-12 (DMEM/F12, Gibco, USA) supplemented with 20% knockout serum replacement (KOSR, Gibco, USA), 1% insulin-transferrin-selenite (Gibco, USA), 1% nonessential amino-acids (NEAA, Gibco, USA), 1% penicillin/streptomycin (Gibco, USA), 0.1 mM  $\beta$ -mercaptoethanol (Sigma-Aldrich, USA), and 100 ng/ml basic fibroblast growth factor (bFGF, Royan Biotech, Iran) in non-adhesive bacterial plates. The medium was renewed every 2 days. When spheroids reached 200-250  $\mu$ m, they were dissociated into single cells with Accutase solution (Sigma-Aldrich, USA), and replated on new bacterial plates at a 1:3 ratio. Cells were treated with 10  $\mu$ M of ROCK inhibitor (ROCKi, Sigma-Aldrich, USA) for the first 2 days.

### Directed differentiation of human embryonic stem cells into cardiogenic mesoderm cells

hESC spheroids (175-200  $\mu$ m in diameter) were subjected to directed differentiation into CMCs as previously described (23). Briefly, spheroids were cultured in basal differentiation medium that contained RPMI 1640 (Gibco, USA) supplemented with 2% B-27 (Gibco, USA), 2 mM L-glutamine (Gibco, USA), 1% penicillin/streptomycin, 1% NEAA, 0.1 mM  $\beta$ -mercaptoethanol, and 12  $\mu$ M of small molecule (SM) CHIR99021 (Stemgent, USA) for 24 h followed by 24 h culture in basal differentiation media without CHIR99021.

### Cardiogenic mesoderm cell culture conditions

To optimize culture of hESC-derived CMCs, we collected CMC spheroids on day 2 post-differentiation and

cultured these spheroids in 4 different culture conditions: i. Suspension culture of CMC spheroids, ii. Adherent culture of CMC spheroids on gelatin, iii. Adherent culture of single CMCs on gelatin, and iv. Adherent culture of single CMCs on Matrigel.

i. In the first approach, we cultured the spheroids of hESC-derived CMCs in a suspension culture condition with non-adhesive bacterial plates. ii. The second culture condition was designed to plate CMC spheroids on gelatin-coated tissue culture dishes to enable them to grow and adhere. The last protocol included enzymatic dissociation of CMC spheroids followed by plating single CMCs on tissue culture dishes to enable them to grow and adhere to the dishes. Briefly, CMC spheroids were treated with Accutase solution for 3 minutes at 37°C and centrifuged at 1500 rpm for 5 minutes. The resultant individual CMCs were cultured on 0.1% gelatin (condition iii) or Matrigel-coated tissue culture plates (condition iv) at a cell density of  $10^5$  cells/cm<sup>2</sup>. Cells were treated overnight with 10  $\mu$ M ROCKi. The media was refreshed every 2 days for all groups by SM-free differentiation medium.

### Flow cytometry and immunostaining

On day 2, RH5 spheroids were dissociated into single cells by using Accutase solution, washed with phosphate-buffered saline (PBS)/0.5% w/v bovine serum albumin (BSA, Sigma-Aldrich, USA), and fixed with 1% paraformaldehyde for 20 minutes at room temperature (RT). Following another wash, the cells were treated with ice-cold 90% methanol (Merck, USA) at 4°C for 15 minutes, washed twice with PBS/0.5% BSA, and incubated overnight with primary antibody MESP1 (Abcam, USA) in PBS/0.5% BSA/0.1% Triton X100 (Sigma-Aldrich, USA) at 4°C. The next day, cells were washed and incubated with Alexa488-conjugated donkey anti-mouse secondary antibody (Invitrogen, USA) in PBS/0.5% BSA/0.1% Triton X100 for 1 hour at RT. Cells were analyzed by a BD FACSCalibur (BD Biosciences, San Jose, CA, USA) system. The data was analyzed by Flowing Software 2.5 (Turku Centre for Biotechnology, Finland).

Immunofluorescent staining of the cells was conducted by plating them on Matrigel-coated plates for 24 hours. The cells were fixed with 1% paraformaldehyde for 20 minutes at RT. In the subsequent steps, we used the same protocol as flow cytometry. Cells were stained with DAPI as a counterstain and observed by a fluorescent microscope (Olympus, Japan). MESP1, Ki67 (Abcam, USA), MHC (Abcam, USA), cTNT (Abcam, USA), and SMA (Abcam, USA) were the primary antibodies. Alexa488-conjugated donkey anti-mouse (Invitrogen, USA), Alexa546-conjugated donkey anti-rabbit (Invitrogen, USA), and Alexa546-conjugated donkey anti-goat (Invitrogen, USA) were

the secondary antibodies. We quantified the positively stained cells by randomly selecting 4 fields for each marker. The number of positive cells were divided by the total cells of each field (stained with DAPI).

### Gene transcription assessment

Total RNA was manually isolated as previously described (5). First strand cDNA synthesis was performed using a PrimeScript™ RT Reagent Kit (Perfect Real Time) (Takara, Japan) and quantitative PCR was done using a SYBR Premix Ex Taq Kit (Takara, Japan) with a Rotor Gene Corbett System (R080873). The  $2^{-\Delta\Delta ct}$  formula was used to calculate relative gene expression of cells at day 2 compared to RH5 undifferentiated cells at day 0. *GAPDH* was the housekeeping gene. All primers' information is summarized in Table 1.

**Table 1:** Primer sequences used for quantitative real time reverse-transcription polymerase chain reaction (RT-PCR)

Gene name	Primer sequences (5'-3')
<i>MESP1</i>	F: ACCTTCGAAGTGGTTCCTTG R: TCCTGCTTGCCTCAAAGTGT
<i>ISL1</i>	F: TACAAAGTTACCAGCCACC R: GGAAGTTGAGAGGACATTGA
<i>PDGFRA</i>	F: TACTACTTGCTATTACAACCACA R: ATCCTCCACGATGACTAAAT
<i>KDR</i>	F: CCAGCCAAGCTGTCTCAGT R: CTGCATGTCAGGTTGCAAAG
<i>NKX2.5</i>	F: TCTATCCACGTGCCCTACAG R: CCTCTGTCTTCTCCAGCTC
<i>MEF2c</i>	F: TCCGAGTTCTTATTCCACC R: ATCCTCCCATTCTTGTC

### Viability and expansion assessment of human embryonic stem cell-derived cardiogenic mesoderm cells

CMCs were dissociated into single cells with the Accutase solution at 37°C for 3 minutes. The enzyme was removed by centrifuging the cell suspension at 1500 rpm for 5 minutes. The resultant cell pellet was dissolved in 5 ml of medium. We mixed 50 µl of the cell suspension with 50 µl of 0.4% trypan blue and loaded 10 µl of the pipetted mixture into a hemocytometer. The cell count was done with a ×10 microscope lens and we calculated the viability of each sample as the ratio of viable cells (without color) to all counted cells. We measured the fold change of expansion after cultivation by dividing the cell count on day 5 to the seeding count.

### Spontaneous and directed cardiogenic differentiation of cardiogenic mesoderm cells

We evaluated the cardiac differentiation potential of the cultured CMCs for both spontaneous and directed differentiations. For spontaneous differentiation, the cultured cells grew for 20 days in basal differentiation medium without any additional SM treatment. Directed differentiation was induced by treatment of the cultured cells with a cardiogenic cocktail that included 5 µM IWP2 (Tocris, England), 5 µM purmorphamine (Stemgent, USA), and 5 µM SB431542 (Cayman, USA) for 2 days. The medium was refreshed every 3 days.

### Electrophysiological study of differentiated cardiogenic mesoderm cells

Functional studies were performed by obtaining the field potential recording according to a previously described method (23). Briefly, the selected beating clusters were mechanically detached under a stereo microscope (Olympus, Japan). Each beating cluster was then plated on a Matrigel-coated multielectrode array (MEA) plate and cultured overnight. On the day of the experiment, we connected the plates to a head stage amplifier to record the field potentials at a sampling rate of 2 kHz.

### Statistical analysis


All datasets were obtained from 3 independent biological replicates and presented as mean ± standard deviation (SD). Statistical analysis was performed with SPSS 16.0 (SPSS Inc., USA) according to unpaired t test or one-way ANOVA with Tukey's post-hoc, depending on the results of the normality test.  $P \leq 0.05$  was considered statistically significant.

### Results


#### Characterization of human embryonic stem cell-derived cardiogenic mesoderm cells

In order to generate hESC-derived CMCs, we subjected the hESCs to cardiogenic differentiation as described previously (Fig.1) (23). *MESP1* expression was evaluated during the first 4 days post-differentiation. Flow cytometry analysis showed the highest percentage of *MESP1*<sup>+</sup> cells ( $82.8 \pm 5.9\%$ ) at day 2 after cardiogenic differentiation (Fig.2A). Therefore, we selected CMCs from this time point for the remainder of the experiments.

CMCs were further characterized by evaluation of expressions of cardiac commitment transcription factors (*ISL1*, *NKX2.5*, and *MEF2c*) and CMC markers (*MESP1*, *KDR*, *PDGFRA*, and *SSEA1*). In addition to substantial upregulation of *MESP1* and *PDGFRA*, CMCs showed an increase in expression of the CPC transcription factors on day 2 compared to undifferentiated hESCs (Fig.2B). They also expressed *SSEA1*, a well-known surface marker for CMCs (11, 14, 24). Immunostaining showed that more than 90% of *MESP1*<sup>+</sup> CMCs were Ki67<sup>+</sup> (Fig.2C, D).



**Fig.1:** Schematic diagram of the strategy used to establish a suitable culture condition for human embryonic stem cell (hESC)-derived cardiogenic mesoderm cells (CMCs). hESCs were expanded and differentiated into cardiomyocytes in suspension culture. One day after treatment of hESC spheroids with small molecule (SM) CHIR99021 (day 2), we obtained the highest percentage of MESP1<sup>+</sup> CMCs. These cells were subjected to 4 different culture conditions in medium without small molecules: i. Suspension culture of CMC spheroids, ii. Adherent culture of CMC spheroids on gelatin, iii. Adherent culture of single CMCs on gelatin, and iv. Adherent culture of single CMCs on Matrigel.




**Fig.2:** Characterization of human embryonic stem cell (hESC)-derived cardiogenic mesoderm cells (CMCs). **A.** Flow cytometry analysis of differentiated hESC spheroids on days 1 to 4 after differentiation for MESP1. We observed the highest percentage of MESP1<sup>+</sup> cells 2 days after differentiation, **B.** Gene expression profile of CMCs. Cardiac transcription factors (*ISL1*, *NKX2.5*, and *MEF2c*), CMC surface markers (*KDR*, *PDGFRα*, and *SSEA1*) and *MESP1* were upregulated compared to undifferentiated hESCs, and **C, D.** Immunostaining of CMCs. More than 90% of the MESP1<sup>+</sup> cells were positive for Ki67 (scale bar: 200 μm).

### ***In vitro* culture of human embryonic stem cell-derived cardiogenic mesoderm cells**

We sought to find the optimal culture condition for hESC-derived CMCs. Differentiated spheroids at the cardiogenic mesoderm stage were cultured for 3 days under 4 conditions: i. Culture of intact spheroids in non-adhesive bacterial plate, ii. Replating of intact spheroids on gelatin-coated plate, iii. Replating of dissociated spheroids on gelatin-coated plate, and iv. Replating of dissociated spheroids on Matrigel-coated plate (Fig.3A-D). Condition

i had decreased viability after 3 days of suspension culture (Fig.3E). However, the cell viability did not change in the other conditions (Fig.3E); therefore, we removed condition i for the rest of the experiments. The culture of dissociated spheroids on Matrigel resulted in higher numbers of CMCs (more than 4-fold) compared to the other conditions (Fig.3F). However, the percentage of MESP1<sup>+</sup> cells did not significantly differ between conditions ii-iv (Fig.3G). Based on the above results, we chose the Matrigel-based adherent culture as an efficient culture condition for the rest of the experiments.




**Fig.3:** Cultivation conditions for human embryonic stem cell (hESC)-derived cardiogenic mesoderm cells (CMCs). After generation of suspended CMCs as spheroids, we cultured these spheroids for 3 days under 4 conditions. **A.** Culture of intact spheroids in non-adhesive bacterial plate (condition i), **B.** Replating of intact spheroids on gelatin-coated plate (condition ii), **C.** Replating of dissociated spheroids on gelatin-coated plate (condition iii), **D.** Replating of dissociated spheroids on Matrigel-coated plate (condition iv) (scale bar: 200  $\mu$ m for all images), **E.** Viability assessment of cultured CMCs 3 days after culture in the 4 different culture conditions (day 5). CMC spheroids in suspension culture (condition i) showed significant reduction in cell viability (~15%) at day 5 compared to day 2 (\*;  $P \leq 0.05$ ), **F.** Expansion capacity of CMCs at day 5 in the 4 different culture conditions. The ratio of output cells to seeding cells was significantly higher in CMCs cultured on Matrigel (condition iv) compared to the other 3 approaches (\*;  $P \leq 0.05$ ), and **G.** Flow cytometry analysis of MESP1<sup>+</sup> cells. There were no significant differences between culture conditions based on the percentage of MESP1<sup>+</sup> cells. D2; Day 2.


### Cardiogenic differentiation of human embryonic stem cell-derived cardiogenic mesoderm cells

We sought to determine if cultured CMCs could maintain their differentiation potency. The CMCs were subjected to both spontaneous and directed differentiation. For spontaneous differentiation, CMCs were kept in culture for an additional 20 days without any special treatment. After 10 days, the CMCs began to generate some clusters. We observed the first beating clusters on day 14 (Fig.4A, B). Spontaneously differentiated CMCs were positive for MHC and  $\alpha$ -SMA as analyzed by immunostaining, which indicated the differentiation potential of CMCs into a cardiac lineage (Fig.4C, D).

In order to direct the CMCs differentiation into cardiomyocytes, we subjected the CMCs to a cardiogenic cocktail (IWP2, purmorphamine, and SB431542). Cells began to beat on day  $7 \pm 1$  post-treatment. The number of beating clusters increased until 100% beating occurred on day  $12 \pm 2$  (Fig.5A). Beating clusters were replated on Matrigel-coated MEA plates on day 30 in order to evaluate their electrophysiological properties. Directed differentiation of CMCs resulted in rhythmic field potentials (Fig.5B). Immunostaining of the cardiac cytoskeletal marker, cTNT, showed a high percentage of cTNT<sup>+</sup> cells ( $93.1 \pm 1.6\%$ ) in CMC-derived cardiomyocytes, which indicated the well-preserved differentiation capacity of cultured CMCs (Fig.5C, D).



**Fig.4:** Spontaneous differentiation potential of cultured cardiogenic mesoderm cells (CMCs) on Matrigel. **A.** Beating clusters generated 12 days after culture of CMCs (scale bar: 200  $\mu$ m), **B.** Higher magnification of beating clusters (arrows) (scale bar: 100  $\mu$ m), **C.** MHC, and **D.**  $\alpha$ -SMA staining of differentiated CMCs. Cells were counterstained with DAPI (scale bar: 100  $\mu$ m).



**Fig.5:** Directed differentiation of human embryonic stem cell (hESC)-derived cardiogenic mesoderm cells (CMCs). **A.** Morphology of beating clusters generated by directed differentiation of CMCs (scale bar: 200  $\mu$ m). **B.** Representative field potentials recorded from differentiated CMCs, and **C, D.** Immunostaining of a cardiomyocyte structural marker (cTNT). More than 90% of cells were cTNT<sup>+</sup> (C: scale bar: 100  $\mu$ m).

## Discussion

hPSCs possess special characteristics such as unlimited self-renewal and differentiation potential, which make them suitable tools for human regenerative medicine. They have been widely used in experimental setups, developmental studies and clinical oriented research. In the cardiovascular field, the generation and culture of hPSC-derived cardiac lineage cells received high attention due to their potential use in cell therapies (11, 25, 26). hPSC-derived cardiovascular cells can be used for developmental research, genetic manipulation, drug screening, and tissue engineering (9, 12, 27, 28). Therefore, a suitable culture condition that could preserve the cellular characteristics of CMCs or CPCs is highly required.

In this study, we attempted to find a culture condition for MESP1<sup>+</sup> CMCs, one of the earliest CPCs during heart development (20, 29-32). In line with our previous report, we identified the highest population of MESP1<sup>+</sup> CMCs on day 2 post-differentiation, which was immediately before cell treatment with the cardiogenic cocktail. *MESP1* expression began on day 1, peaked on day 2, and downregulated after cardiogenic induction (23). The gene expression profile of MESP1<sup>+</sup> CMCs showed expression of cardiac transcription factors *ISL1*, *NKX2.5*, and *MEF2c* as well as CMC markers *MESP1* and *PDGFR $\alpha$*  which exhibited a typical pattern of early CPCs (14, 20, 26, 33). The CMCs were positive for Ki67, which showed their

proliferative state. CMC spheroids were used to find the best culture strategy that had the most expansion capacity. These CMC spheroids were enriched for more than 80% MESP1<sup>+</sup> cells; therefore, there was no need for additional cell purification with sorting systems (34).

In contrast to published protocols that used gelatin as a culture substrate for ISL1<sup>+</sup>/MEF2c<sup>+</sup> and Nkx2.5<sup>+</sup> CPCs (25, 35), the MESP1<sup>+</sup> CMCs in the current study greatly attached to, spread, and grew on Matrigel. Matrigel is a well-known substrate for several types of stem cells, including hPSCs (36). Of note, different cell types have different attachment properties, which highlights the importance of finding a suitable culture substrate for each cell type (37).

Based on our results, the Matrigel-based adherent culture of single CMCs was identified as an efficient culture condition among the 4 different tested culture conditions. We did not use any maintenance medium for the CMCs culture; therefore, the percentage of MESP1<sup>+</sup> cells decreased after 3 days in culture, which might show the initiation of spontaneous differentiation. However, to further evaluate the differentiation potency of cultured CMCs, we subjected them to spontaneous and directed differentiation. Spontaneously differentiated cells generated cardiomyocytes as well as smooth muscle cells that stained for MHC and SMA, respectively. However, after directed differentiation, approximately 93% of cells were positive for cTNT, which showed their

high capacity for differentiation into cardiomyocytes, consistent with our previous report (23). During heart development, *MESPI* cooperates its paralogous gene *MESP2* to initiate cardiogenesis based on the neighboring signals. Additionally, *MESPI* expression is essential for epithelial-mesenchymal transition (EMT) which promotes the migration of CPCs from the primitive streak (19, 29).

Matrigel can affect cell morphology and differentiation capacity due to its composition (38). Additionally, Matrigel can retain cell properties, which is in line with our results. The Matrigel-based adherent culture of CMCs might provide a suitable condition for application of genetic tools such as siRNA gene knockdown as well as small molecule/drug screenings (35).

## Conclusion

We attempted to find a suitable culture condition for hESC-derived *MESPI*<sup>+</sup> cells. Matrigel-based adherent culture of CMCs could well preserve their characteristics that included proliferation and differentiation capacity into cardiac lineages, which would facilitate their application for further cell manipulations.

## Acknowledgements

This study was financially supported by a grant from Royan Institute, the Iran National Science Foundation (INSF # 9600013), and Iran Science Elites Federation to H.B. The authors would like to thank Seyed Mahdi Hosseini for his time and assistance. There is no conflict of interest in this study.

## Authors' Contributions

S.V.; Contributed to all experimental work, data and statistical analysis and paper draft preparation. S.P.; Performed electrophysiological recording and manuscript writing. N.A.; Scientific adviser of the project. B.B.; Scientific supervisor of the project and finalized manuscript. H.B.; Scientific supervisor of the project, main idea, and finalized manuscript. All authors approved the final version of this manuscript.

## References

1. Wu SM, Chien KR, Mummery C. Origins and fates of cardiovascular progenitor cells. *Cell*. 2008; 132(4): 537-543.
2. Chamuleau SAJ, Vrijnsen KR, Rokosh DG, Tang XL, Piek JJ, Bolli R. Cell therapy for ischaemic heart disease: focus on the role of resident cardiac stem cells. *Neth Heart J*. 2009; 17(5): 199-207.
3. Zhao X, Huang L. Cardiac stem cells: a promising treatment option for heart failure. *Exp Ther Med*. 2013; 5(2): 379-383.
4. Wang WE, Chen X, Houser SR, Zeng C. Potential of cardiac stem/progenitor cells and induced pluripotent stem cells for cardiac repair in ischaemic heart disease. *Clin Sci (Lond)*. 2013; 125(7): 319-327.
5. Vahdat S, Mousavi SA, Omrani G, Gholampour M, Sotoodehnejadnematalahi F, Ghazizadeh Z, et al. Cellular and molecular characterization of human cardiac stem cells reveals key features essential for their function and safety. *Stem Cells Dev*. 2015; 24(12): 1390-1404.
6. Bondue A, Tannler S, Chiapparo G, Chabab S, Ramialison M, Paulissen C, et al. Defining the earliest step of cardiovascular progenitor specification during embryonic stem cell differentiation. *J*

- Cell Biol. 2011; 192(5):751-765.
7. Nsair A, Schenke-Layland K, Van Handel B, Evseenko D, Kahn M, Zhao P, et al. Characterization and therapeutic potential of induced pluripotent stem cell-derived cardiovascular progenitor cells. *PLoS One*. 2012; 7(10): e45603.
8. Li G, Plonowska K, Kuppusamy R, Sturzu A, Wu SM. Identification of cardiovascular lineage descendants at single-cell resolution. *Development*. 2015; 142(5): 846-857.
9. Garreta E, de Onate L, Fernandez-Santos ME, Oria R, Tarantino C, Climent AM, et al. Myocardial commitment from human pluripotent stem cells: Rapid production of human heart grafts. *Biomaterials*. 2016; 98: 64-78.
10. Cagavi E, Bartulos O, Suh CY, Sun B, Yue Z, Jiang Z, et al. Functional cardiomyocytes derived from Isl1 cardiac progenitors via *Bmp4* stimulation. *PLoS One*. 2014; 9(12): e110752.
11. Menasche P, Vanneau V, Fabreguettes JR, Bel A, Tosca L, Garcia S, et al. Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: a translational experience. *Eur Heart J*. 2015; 36(12): 743-750.
12. Drowley L, Koonce C, Peel S, Jonebring A, Plowright AT, Kattman SJ, et al. Human induced pluripotent stem cell-derived cardiac progenitor cells in phenotypic screening: a transforming growth factor-beta type 1 receptor kinase inhibitor induces efficient cardiac differentiation. *Stem Cells Transl Med*. 2016; 5(2): 164-174.
13. Mauritz C, Martens A, Rojas SV, Schnick T, Rathert C, Schecker N, et al. Induced pluripotent stem cell (iPSC)-derived Fik-1 progenitor cells engraft, differentiate, and improve heart function in a mouse model of acute myocardial infarction. *Eur Heart J*. 2011; 32(21): 2634-2641.
14. Blin G, Nury D, Stefanovic S, Neri T, Guillevic O, Brinon B, et al. A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. *J Clin Invest*. 2010; 120(4): 1125-1139.
15. Fernandes S, Chong JJH, Paige SL, Iwata M, Torok-Storb B, Keller G, et al. Comparison of human embryonic stem cell-derived cardiomyocytes, cardiovascular progenitors, and bone marrow mononuclear cells for cardiac repair. *Stem Cell Reports*. 2015; 5(5): 753-762.
16. Paige SL, Plonowska K, Xu A, Wu SM. Molecular regulation of cardiomyocyte differentiation. *Circ Res*. 2015; 116(2): 341-353.
17. Sturzu AC, Wu SM. Developmental and regenerative biology of multipotent cardiovascular progenitor cells. *Circ Res*. 2011; 108(3): 353-364.
18. Buikema JW, Van Der Meer P, Sluijter JP, Domian JJ. Concise review: engineering myocardial tissue: the convergence of stem cells biology and tissue engineering technology. *Stem Cells*. 2013; 31(12): 2587-2598.
19. Chiapparo G, Lin X, Lescroart F, Chabab S, Paulissen C, Pitisci L, et al. *Mesp1* controls the speed, polarity, and directionality of cardiovascular progenitor migration. *J Cell Biol*. 2016; 213(4): 463-477.
20. Liu Y, Chen L, Diaz AD, Benham A, Xu X, Wijaya CS, et al. *Mesp1* marked cardiac progenitor cells repair infarcted mouse hearts. *Sci Rep*. 2016; 6: 31457.
21. Werner P, Latney B, Deardorff MA, Goldmuntz E. *MESP1* mutations in patients with congenital heart defects. *Hum Mutat*. 2016; 37(3): 308-314.
22. Larijani MR, Seifinejad A, Pournasr B, Hajihoseini V, Hassani SN, Totonchi M, et al. Long-term maintenance of undifferentiated human embryonic and induced pluripotent stem cells in suspension. *Stem Cells Dev*. 2011; 20(11): 1911-1923.
23. Fonoudi H, Ansari H, Abbasalizadeh S, Larijani MR, Kiani S, Hashemizadeh S, et al. A universal and robust integrated platform for the scalable production of human cardiomyocytes from pluripotent stem cells. *Stem Cells Transl Med*. 2015; 4(12): 1482-1494.
24. Menasche P, Vanneau V, Hagege A, Bel A, Cholley B, Cacciapuoti I, et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. *Eur Heart J*. 2015; 36(30): 2011-2017.
25. Lei IL, Bu L, Wang Z. Derivation of cardiac progenitor cells from embryonic stem cells. *J Vis Exp*. 2015; (95): 52047.
26. Birket MJ, Mummery CL. Pluripotent stem cell derived cardiovascular progenitors--a developmental perspective. *Dev Biol*. 2015; 400(2 ):169-179.
27. Den Hartogh SC, Wolstencroft K, Mummery CL, Passier R. A comprehensive gene expression analysis at sequential stages of in vitro cardiac differentiation from isolated *MESP1*-expressing-mesoderm progenitors. *Sci Rep*. 2016;6:19386.



28. Christoforou N, Liao B, Chakraborty S, Chellapan M, Bursac N, Leong KW. Induced pluripotent stem cell-derived cardiac progenitors differentiate to cardiomyocytes and form biosynthetic tissues. *PLoS One*. 2013;8(6): e65963.
29. Van Vliet P, Wu SM, Zaffran S, Puceat M. Early cardiac development: a view from stem cells to embryos. *Cardiovasc Res*. 2012; 96(3): 352-362.
30. Saga Y, Miyagawa-Tomita S, Takagi A, Kitajima S, Miyazaki JI, Inoue T. *MesP1* is expressed in the heart precursor cells and required for the formation of a single heart tube. *Development*. 1999; 126(15): 3437-3447.
31. Bondue A, Blanpain C. *Mesp1*: a key regulator of cardiovascular lineage commitment. *Circ Res*. 2010; 107(12): 1414-1427.
32. Liang Q, Xu C, Chen X, Li X, Lu C, Zhou P, et al. The roles of *Mesp* family proteins: functional diversity and redundancy in differentiation of pluripotent stem cells and mammalian mesodermal development. *Protein Cell*. 2015; 6(8): 553-561.
33. Cao N, Liang H, Huang J, Wang J, Chen Y, Chen Z, et al. Highly efficient induction and long-term maintenance of multipotent cardiovascular progenitors from human pluripotent stem cells under defined conditions. *Cell Res*. 2013; 23(9): 1119-1132.
34. Kattman SJ, Witty AD, Gagliardi M, Dubois NC, Niapour M, Hotta A, et al. Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. *Cell Stem Cell*. 2011; 8(2): 228-240.
35. Huang X, Wu SM. Isolation and functional characterization of pluripotent stem cell-derived cardiac progenitor cells. *Curr Protoc Stem Cell Biol*. 2010; Chapter 1: Unit 1F. 10.
36. Totonchi M, Taei A, Seifinejad A, Tabebordbar M, Rassouli H, Farrokhi A, et al. Feeder- and serum-free establishment and expansion of human induced pluripotent stem cells. *Int J Dev Biol*. 2010; 54(5): 877-886.
37. Baharvand H, Azarnia M, Parivar K, Ashtiani SK. The effect of extracellular matrix on embryonic stem cell-derived cardiomyocytes. *J Mol Cell Cardiol*. 2005; 38(3): 495-503.
38. Highet AR, Zhang VJ, Heinemann GK, Roberts CT. Use of Matrigel in culture affects cell phenotype and gene expression in the first trimester trophoblast cell line HTR8/SVneo. *Placenta*. 2012; 33(7): 586-588.

Archive of SID